TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22751028

Group type: EXPERIMENTAL
Intervention: Pregabalin + Dexamethasone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 108
Study: 21050887

Group type: EXPERIMENTAL
Intervention: DMB‐SR floating tablets (HPMC K4M 25 mg, sodium bicarbonate 20 mg, hexadecanol 18 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional DMB‐SR tablets
Number of subjects: 0
Study: 18316794

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 693

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 693
Study: 16315025

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen + 2.5 mg medroxyprogesterone acetate (CEE/MPA)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: 1 mg 17beta estradiol + 0.5 mg norethindrone acetate (E2/NETA)
Number of subjects: 246
Study: 14570797

Group type: EXPERIMENTAL
Intervention: Single bolus of propofol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Infusion of propofol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bolus followed by infusion of propofol
Number of subjects: 75
Study: 10195538

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 2 mg/mL with fentanyl 4 microg/mL (Group R4F)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Epidural ropivacaine 2 mg/mL alone (Group R)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Epidural ropivacaine 2 mg/mL with fentanyl 1 microg/mL (Group R1F)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Epidural ropivacaine 2 mg/mL with fentanyl 2 microg/mL (Group R2F)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 2 mg/mL with fentanyl (all doses)
Number of subjects: 244
Study: 7756100

Group type: EXPERIMENTAL
Intervention: Physostigmine transdermal system (PTS)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral solution
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous infusion
Number of subjects: 6
Study: 2179137

Group type: EXPERIMENTAL
Intervention: Ampicillin plus sulbactam
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 83
Study: 231299

Group type: EXPERIMENTAL
Intervention: 500 mg cephradine every 6 h for 7 days
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 400 mg pivmecillinam every 6 h for 7 days
Number of subjects: 98

Group type: COMPARATOR
Intervention: 500 mg cephradine
Number of subjects: 98

Group type: COMPARATOR
Intervention: 400 mg pivmecillinam
Number of subjects: 98
Study: 30040135

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg, single oral dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5 mg intravenous amisulpride
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40 mg intravenous amisulpride
Number of subjects: 40
Study: 28638011

Group type: COMPARATOR
Intervention: Group I (patients without ventral hernias)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Group II (patients with ventral hernias)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Subgroup AI (primary operation)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Subgroup BI (re-operation)
Number of subjects: 141
Study: 27900198

Group type: EXPERIMENTAL
Intervention: Rocker-sole shoes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flat-sole shoes
Number of subjects: 20
Study: 24694924

Group type: EXPERIMENTAL
Intervention: Synthetic oxytocin (24 IU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 40
Study: 22113087

Group type: EXPERIMENTAL
Intervention: Org 25935 (glycine transporter-1 inhibitor)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19189246

Group type: EXPERIMENTAL
Intervention: S. chrysotrichum herbal medicinal product (Sc-hmp), standardized in 1.89 mg of SC-2, administered as vaginal suppositories daily for 7 nights
Number of subjects: 101

Group type: COMPARATOR
Intervention: Ketoconazole (400 mg), administered as vaginal suppositories daily for 7 nights
Number of subjects: 101
Study: 17209694

Group type: EXPERIMENTAL
Intervention: Matched distraction trial for low monitors
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Matched sensation monitoring trial for high monitors
Number of subjects: 178

Group type: COMPARATOR
Intervention: Mismatched sensation monitoring trial for low monitors
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Pain tolerance scores
Number of subjects: 178

Group type: COMPARATOR
Intervention: Pain intensity
Number of subjects: 178

Group type: COMPARATOR
Intervention: Pain affect
Number of subjects: 178

Group type: COMPARATOR
Intervention: Anxiety
Number of subjects: 178
Study: 16215875

Group type: EXPERIMENTAL
Intervention: Modified curriculum intervention schools
Number of subjects: 508
Study: 11991625

Group type: EXPERIMENTAL
Intervention: 40 g lactulose meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: 40 g sucrose meal followed by colonic infusion of 40 g lactulose
Number of subjects: 8
Study: 9704778

Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B6 supplementation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B6 supplementation with aspirin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Previous pregnancies (control group)
Number of subjects: 37
Study: 8556974

Group type: EXPERIMENTAL
Intervention: Mazindol (2 mg QD)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31714583

Group type: EXPERIMENTAL
Intervention: Glucagon (300/150 μg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 12
Study: 29596222

Group type: EXPERIMENTAL
Intervention: Micafungin (MCA) 10 mg/kg/d for ≥21 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amphotericin B Deoxycholate (AmB-D) 1 mg/kg/d for ≥21 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Micafungin (MCA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amphotericin B Deoxycholate (AmB-D)
Number of subjects: 30
Study: 28723799

Group type: EXPERIMENTAL
Intervention: TACE with Huaier granule
Number of subjects: 62

Group type: COMPARATOR
Intervention: TACE with GSPs plus lobaplatin chemotherapy
Number of subjects: 62
Study: 25028065

Group type: EXPERIMENTAL
Intervention: Encenicline (alpha-7 nicotine agonist)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 23319176

Group type: EXPERIMENTAL
Intervention: Single dose of HZ vaccine (0.65 mL)
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Two doses of HZ vaccine at 0 and 1 month
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Two doses of HZ vaccine at 0 and 3 months
Number of subjects: 759

Group type: COMPARATOR
Intervention: Two-dose vaccination (both schedules)
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: All three vaccination schedules
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: HZ vaccine
Number of subjects: 759
Study: 22018642

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg for 6 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 19253247

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 135

Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 135

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 135
Study: 16717170

Group type: EXPERIMENTAL
Intervention: BNP testing (n = 225)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Standard assessment (n = 227)
Number of subjects: 452
Study: 15571954

Group type: EXPERIMENTAL
Intervention: Intraventricular chemotherapy (IT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-intrathecal treatment (non-IT)
Number of subjects: 35
Study: 11768138

Group type: EXPERIMENTAL
Intervention: Objects labeled with novel nouns
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Objects labeled with familiar nouns
Number of subjects: 144

Group type: COMPARATOR
Intervention: Objects not labeled
Number of subjects: 144
Study: 9415525

Group type: EXPERIMENTAL
Intervention: Deodorant catamenial pads
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Non-deodorant catamenial pads
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 190
Study: 8106654

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 to 40 mg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Fluoxetine (20 to 60 mg)
Number of subjects: 106
Study: 2446057

Group type: EXPERIMENTAL
Intervention: Ketanserin (20-40 mg b.i.d.)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Methyldopa (250-500 mg b.i.d.)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 119

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 119
Study: 30400774

Group type: EXPERIMENTAL
Intervention: Supervised physical activity intervention consisting of 16 weeks structured exercise, physical activity self‐monitoring and motivational coaching.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care/minimal intervention (Control group).
Number of subjects: 200
Study: 27571100

Group type: EXPERIMENTAL
Intervention: Gluten Contamination Elimination Diet (GCED) for 3 months (Cohort A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Standard gluten-free diet (GFD) for a minimum of 2 years (Cohort B)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Early control (baseline after 12-18 months of GFD)
Number of subjects: 29
Study: 24060164

Group type: EXPERIMENTAL
Intervention: AutoAdhesive mesh (AA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Classic Lichtenstein technique with sutured polypropylene mesh (CL)
Number of subjects: 90
Study: 22956167

Group type: EXPERIMENTAL
Intervention: Pre-filled pen (PFP)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Pre-filled syringe (PFS)
Number of subjects: 640
Study: 20569086

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 18520294

Group type: EXPERIMENTAL
Intervention: Sorafenib (monotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sorafenib (in combination with chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sorafenib (in combination with epidermal growth factor receptor inhibitors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bevacizumab (in combination with cytotoxic chemotherapy)
Number of subjects: 0
Study: 15893182

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg and fenofibrate 200 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fenofibrate 200 mg
Number of subjects: 56
Study: 12887139

Group type: EXPERIMENTAL
Intervention: Tyrosine 150 mg/kg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: D-amphetamine 20 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Phentermine 37.5 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg/70 kg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 10505365

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (evaluated and treated by telemedicine nurse and rural emergency physician via telemedicine link)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (diagnosed and treated by suburban emergency physician)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 8636359

Group type: COMPARATOR
Intervention: Bread (approximately 85 kcal)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bread plus meat (approximately 205 kcal)
Number of subjects: 6
Study: 1646924

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atipamezole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma NE concentration
Number of subjects: 0
Study: 6799074

Group type: EXPERIMENTAL
Intervention: Guided transtracheal brushing-washing
Number of subjects: 20
Study: 31971678

Group type: EXPERIMENTAL
Intervention: Elagolix plus add-back therapy (300 mg twice daily with estradiol 1 mg and norethindrone acetate 0.5 mg once daily)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Elagolix alone
Number of subjects: 790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 790
Study: 31319769

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Expectancies about cannabis use
Number of subjects: 311
Study: 27568350

Group type: EXPERIMENTAL
Intervention: Intensive nutritional care (INC) with six meetings with a dietitian
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group based on European and American guidelines
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Meta-analysis of nutritional care
Number of subjects: 87
Study: 26773325

Group type: EXPERIMENTAL
Intervention: lexaptepid pegol (1.2 mg·kg(‐1) i.v.)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: lexaptepid pegol (doses from 0.3 to 4.8 mg·kg(‐1))
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: lexaptepid pegol (≥2.4 mg·kg(‐1))
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: lexaptepid pegol (s.c. administration)
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 24268678

Group type: EXPERIMENTAL
Intervention: Mandatory iodine fortification of bread and salt
Number of subjects: 2465
Study: 21997675

Group type: EXPERIMENTAL
Intervention: Ingested water (300 ml labeled with D₂O; osmolality <20 mOsm kg(‐1))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: N-CM (non-compartmental model)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1-CM (one-compartment model)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2-CM (two-compartment model)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2-CM
Number of subjects: 36
Study: 19294962

Group type: EXPERIMENTAL
Intervention: Fermented ginseng (FG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17489911

Group type: EXPERIMENTAL
Intervention: Mail/web condition (initial mailed survey followed by web survey to nonrespondents)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Web/mail condition (initial web survey followed by mailed survey to nonrespondents)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Web/mail condition
Number of subjects: 500

Group type: COMPARATOR
Intervention: Mail/web condition
Number of subjects: 500
Study: 15462687

Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5mg, 25mg, or 50mg, combined, N = 10026)
Number of subjects: 17072

Group type: COMPARATOR
Intervention: NSAIDs (ibuprofen, diclofenac, nabumetone, or naproxen, combined, N = 7046)
Number of subjects: 17072
Study: 15884512

Group type: EXPERIMENTAL
Intervention: Subconjunctival MMC (0.2 mg/ml for 3 minutes)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intrascleral MMC (0.2 mg/ml for 3 minutes)
Number of subjects: 41
Study: 9598903

Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (10 mg/m2 body surface area/wk)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-penicillamine, hydroxychloroquine, auranofin, very low dose methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Definitions requiring 20 to 30% improvement in 3 to 4 core outcome variables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Definition resembling the Paulus criteria (4 of 6 core set variables improved by > or = 20%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Definition (3 of 6 core set variables improved by > or = 30%, not more than one worsening by > 30%)
Number of subjects: 0
Study: 8159444

Group type: COMPARATOR
Intervention: Active control: palatal splint worn 24 h/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Treatment: full occlusal splint worn 24 h/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Passive control: full occlusal splint worn only 30 min at each appointment
Number of subjects: 63
Study: 3166632

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 30721109

Group type: EXPERIMENTAL
Intervention: 12-week Internet-based intervention (deprexis)
Number of subjects: 483
Study: 30768428

Group type: EXPERIMENTAL
Intervention: Telemonitoring program
Number of subjects: 0
Study: 26762375

Group type: EXPERIMENTAL
Intervention: Parent-child mediation intervention
Number of subjects: 111

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 111
Study: 25886281

Group type: EXPERIMENTAL
Intervention: Mental simulation exercise presented in print format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Challenging online self-control training exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Easy training exercise with little self-control demand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control irrelevant visualization exercise
Number of subjects: 0
Study: 23681967

Group type: EXPERIMENTAL
Intervention: Recombinant human ACE2 (rhACE2) 100-1200 μg/kg single dose
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Recombinant human ACE2 (rhACE2) 400 μg/kg repeated dosing for 3 or 6 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21347821

Group type: EXPERIMENTAL
Intervention: NiTi Hand CAC 30
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hand-sewn (control)
Number of subjects: 44
Study: 19685109

Group type: EXPERIMENTAL
Intervention: Priming with vecuronium (0.02 mg.kg(‐1))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Priming with rocuronium (0.06 mg.kg(‐1))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.2 microg.kg(‐1).min(‐1) (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Remifentanil at 0.7 microg.kg(‐1).min(‐1) (group B)
Number of subjects: 100
Study: 17850526

Group type: EXPERIMENTAL
Intervention: Three-tier formulary adoption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-tier formulary (comparison group)
Number of subjects: 0
Study: 15271118

Group type: EXPERIMENTAL
Intervention: Nutrition supplements provided between breakfast and lunch for 21 consecutive days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Habitual intake for 21 consecutive days
Number of subjects: 34
Study: 12817353

Group type: EXPERIMENTAL
Intervention: Educational outreach
Number of subjects: 233

Group type: COMPARATOR
Intervention: Postal guideline dissemination
Number of subjects: 233
Study: 9685273

Group type: EXPERIMENTAL
Intervention: Intensive cognitive behaviour therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Supportive counselling and routine care
Number of subjects: 87

Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 87
Study: 8085511

Group type: EXPERIMENTAL
Intervention: Domiciliary rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital-based rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient departments
Number of subjects: 0
Study: 2546659

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg b.i.d., orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1002350

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31300907

Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreaticoduodenectomy (L-PD)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Open pancreaticoduodenectomy (O-PD)
Number of subjects: 149
Study: 28893812

Group type: EXPERIMENTAL
Intervention: Scribes
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Scribe (Control)
Number of subjects: 0
Study: 26276228

Group type: EXPERIMENTAL
Intervention: FFPE-T (formalin-fixed paraffin embedded tumor)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: FFPE-LN (formalin-fixed paraffin embedded lymph node)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Whole blood
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: FFPE-T
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: FFPE-LN
Number of subjects: 114
Study: 23659666

Group type: EXPERIMENTAL
Intervention: Erythropoietin (1000 IU/kg for three daily doses)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Phenobarbital (40 mg/kg single dose)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (supportive treatment)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control
Number of subjects: 67
Study: 21157296

Group type: EXPERIMENTAL
Intervention: Efavirenz/tenofovir/emtricitabine (n = 19)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Efavirenz/zidovudine/lamivudine (n = 31)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: K103N viral load at least 2000 copies/ml
Number of subjects: 487
Study: 19411796

Group type: EXPERIMENTAL
Intervention: Multimedia learning program for DM diet education using standardized patients
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Regular lectures and multimedia learning program
Number of subjects: 108

Group type: COMPARATOR
Intervention: Regular lectures only
Number of subjects: 108
Study: 17715458

Group type: EXPERIMENTAL
Intervention: Joint action with four hands (dyads)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Joint action with two hands (dyads)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation and relative phase analyses of force-time functions in dyads
Number of subjects: 20
Study: 15069730

Group type: EXPERIMENTAL
Intervention: Hemoperfusion adsorption therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Plasma exchange therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Plasma exchange plus hemoperfusion adsorption therapy
Number of subjects: 75
Study: 11834182

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Cupressus arizonica
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20